Back to top
more

Astria Therapeutics (ATXS)

(Real Time Quote from BATS)

$6.42 USD

6.42
5,309

-0.25 (-3.75%)

Updated Aug 8, 2025 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year.

Zacks Equity Research

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

Zacks Equity Research

Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?

by Zacks Equity Research

Astria Therapeutics (ATXS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Suncor (SU) Q3 Earnings Preview: What Investors Need to Know

by Zacks Equity Research

Improvement in production and lower costs are likely to have buoyed the third-quarter earnings of Suncor Energy (SU), only to be offset by a drop in realized prices.

Zacks Equity Research

Will NexTier Merger Boost Patterson-UTI's (PTEN) Q3 Earnings?

by Zacks Equity Research

Patterson-UTI Energy (PTEN) beat the Zacks Consensus Estimate for earnings thrice in the last four quarters and met in the other, resulting in an earnings surprise of 20.5%, on average.

Zacks Equity Research

Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug

by Zacks Equity Research

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.

Zacks Equity Research

Here's What Could Help Astria Therapeutics, Inc. (ATXS) Maintain Its Recent Price Strength

by Zacks Equity Research

Astria Therapeutics, Inc. (ATXS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 70% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 70.1% in Astria Therapeutics, Inc. (ATXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Lantheus (LNTH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

Zacks Equity Research

What Makes Astria Therapeutics, Inc. (ATXS) a Good Fit for 'Trend Investing'

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Astria Therapeutics, Inc. (ATXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 234% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Astria Therapeutics, Inc. (ATXS) points to a 234.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

How Much Upside is Left in Astria Therapeutics, Inc. (ATXS)? Wall Street Analysts Think 229%

by Zacks Equity Research

The consensus price target hints at a 229.5% upside potential for Astria Therapeutics, Inc. (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.